THYROID TABLET

国: カナダ

言語: 英語

ソース: Health Canada

即購入

ダウンロード 製品の特徴 (SPC)
04-10-2022

有効成分:

THYROID

から入手可能:

SEARCHLIGHT PHARMA INC

ATCコード:

H03AA05

INN(国際名):

THYROID GLAND PREPARATIONS

投薬量:

30MG

医薬品形態:

TABLET

構図:

THYROID 30MG

投与経路:

ORAL

パッケージ内のユニット:

100/500

処方タイプ:

Prescription

治療領域:

THYROID AGENTS

製品概要:

Active ingredient group (AIG) number: 0107351004; AHFS:

認証ステータス:

APPROVED

承認日:

2022-10-04

製品の特徴

                                



PRESCRIBING INFORMATION
Pr
THYROID
Desiccated Thyroid
Thyroid Tablets, C.S.D.
30, 60, 125 mg
Hypothyroidism Therapy
Searchlight Pharma Inc.
1600 Notre-Dame West, suite 312
Montreal, QC
H3J 1M1
Date of Preparation: OCT 4, 2022
Submission Control No: 267094




PRESCRIBING INFORMATION
PR THYROID
DESICCATED THYROID
THYROID TABLETS, C.S.D.
30, 60 AND 125 MG
THERAPEUTIC CLASSIFICATION
HYPOTHYROIDISM THERAPY
ACTIONS AND CLINICAL PHARMACOLOGY
The principal pharmacologic effect of exogenous thyroid hormones is to
increase the metabolic
rate of body tissues.
The normal thyroid gland contains approximately 200 µg of
levothyroxine (T4)/g of gland, and 15
µg of triiodothyronine (T3)/g. The ratio of these two hormones in the
circulation does not
represent the ratio in the thyroid gland, since about 80% of
peripheral triiodothyronine comes
from monodeiodination of the outer ring of levothyroxine. Peripheral
monodeiodination of
levothyroxine at the 5 position (inner ring) also results in the
formation of reverse
triiodothyronine (r T3), which is calorigenically inactive. These
facts would seem to advocate
levothyroxine as the treatment of choice for the hypothyroid patient
and to mitigate against the
administration of hormone combinations which while normalizing
thyroxine levels, may produce
triiodothyronine levels in the thyrotoxic range.
Triiodothyronine (T3) level is low in the fetus and newborn, in old
age, in chronic caloric
deprivation, hepatic cirrhosis, renal failure, surgical stress, and
chronic illnesses representing
what has been called the “low triiodothyronine syndrome.”
Pharmacokinetics:
Animal studies have shown that T4 is only partially absorbed from the
gastrointestinal tract. The degree of absorption is dependent on the
vehicle used for its
administration and by the character of the intestinal contents, the
intestinal flora, including
plasma protein, soluble dietary factors, all of which bind thyroid and
thereby make it unavailable
for diffusion. Only 41% is absorbed whe
                                
                                完全なドキュメントを読む
                                
                            

他の言語のドキュメント

製品の特徴 製品の特徴 フランス語 04-10-2022

この製品に関連するアラートを検索

ドキュメントの履歴を表示する